The two GLP-1 treatments available are sold under the brand names Byetta and Victoza. The drugs, however, are not very p…
Bydureon
My Wake Up Call: Bydureon and Possible Cancer Risk?
Last week, I attended the Second Annual Diabetes Symposium at the Thomas Jefferson University. Surrounded by endocrinol…
FDA To Re-Evaluate Type 2 Diabetes Drugs Following New Research
The FDA is evaluating unpublished new findings by a group of academic researchers that suggest an increased risk of panc…
Amylin’s New Type 2 Diabetes Treatment, Bydureon, Now Available in US Pharmacies
The newly approved type 2 diabetes drug Bydureon, made by Amylin Pharmaceuticals and Alkermes plc, is now available by …
FDA Approves Type 2 Diabetes Drug Bydureon
Amylin Pharmaceuticals, Inc. and Alkermes plc received FDA approval for Bydureon, a next generation once-weekly treatmen…
Type 2 Drug Bydureon Proves More Effective Than Other Common Diabetes Treatments
Amylin Pharmaceuticals, Eli Lilly and Alkermes announced new analyses from the DURATION-3 and DURATION-4 trials demonstr…
New Type 2 Diabetes Drug, Bydureon, Shows Positive Effect on A1c and Weight
Amylin, Eli Lilly and Alkermes, announced results from long-term extensions of the DURATION-1 and 3 studies evaluating B…
Lilly and Amylin Type 2 Diabetes Drug, Bydureon, Approved for Marketing in Europe
The European Commission has granted marketing authorization to Eli Lilly, Amylin Pharmaceuticals and Alkermes' type 2 di…
Bydureon Receives Positive Opinion From The European Medicines Agency
Eli Lilly and Company, Amylin Pharmaceuticals and Alkermes announced today that the Committee for Medicinal Products for…
Positive Results for Once Monthly Type 2 Diabetes Drug
Positive results from a phase 2 study evaluating the effects of a once-monthly injectable suspension formulation of exen…
